/ Once weekly carfilzomib, promising for refractory myeloma patients - Speciality Medical Dialogues
This site is intended for Healthcare professionals only.

Once weekly carfilzomib, promising for refractory myeloma patients


Once weekly carfilzomib, promising for refractory myeloma patients

Once weekly carfilzomib appears safe and more effective with a convenient dosing regimen versus the twice-weekly schedule for the treatment of patients with relapsed and refractory multiple myeloma, according to data from a study published in The Lancet Oncology. 

Philippe Moreau, Department of Hematology, University Hospital of Nantes, France, and colleagues conducted the phase III ARROW trial to compare progression-free survival in patients with relapsed and refractory multiple myeloma given once weekly carfilzomib or twice weekly carfilzomib.

Twice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly carfilzomib dosing, established the maximum tolerated dose at 70 mg/m2 in combination with dexamethasone.

In the trial, 478 patients with R/R MM from 118 sites were randomized to receive once-weekly or twice-weekly carfilzomib in combination with dexamethasone in 28-day cycles until disease progression or unacceptable toxicity. The patients had previously received 2–3 treatments, including a proteasome inhibitor and an immunomodulatory agent.

Patients in the once-weekly carfilzomib group received 30-minute intravenous infusion on days 1, 8 and 15 of all cycles (20 mg/m2 on day 1 in cycle 1, 70 mg/m2 thereafter). Those in the twice-weekly carfilzomib group received 10-minute intravenous infusion on days 1, 2, 8, 9, 15 and 16 (20 mg/m2 on days 1 and 2 in cycle 1, 27 mg/m2thereafter). Dexamethasone was given at a dosage of 40 mg on days 1, 8 and 15 in all cycles and on day 22 of cycles 1–9 only.

Median carfilzomib exposure was 38 weeks in the once-weekly group and 29.1 weeks in the twice-weekly group, while median dexamethasone exposure was 37.1 weeks and 29.1 weeks, respectively.

Key Findings:

  • In an interim analysis of the trial, patients randomized to receive once-weekly carfilzomib (70 mg/m2) plus dexamethasone showed a significant 31 percent improvement in progression-free survival (PFS) vs those who received twice-weekly carfilzomib (27 mg/m2) plus dexamethasone (median, 11.2 months vs 7.6 months; hazard ratio [HR], 0.69; p=0.0029).
  • In addition to improvement in the primary endpoint of PFS, patients on once-weekly carfilzomib also had a significantly higher overall response rate [ORR] vs those on the currently approved twice-weekly dosing regimen (62.9 percent vs 40.8 percent).
  • Complete response or better was achieved by 7 percent of patients on once-weekly carfilzomib vs 2 percent of those on twice-weekly carfilzomib, while very good partial response or better was achieved by 34 percent vs 13 percent of the patients.
  • Compared with the twice-weekly dosing schedule, once-weekly carfilzomib showed a favorable benefit-risk profile and is more convenient.
  • Grade ≥3 adverse events occurred in 68 percent of patients on once-weekly carfilzomib vs 62 percent of patients on twice-weekly dosing.
  • Frequent grade ≥3 adverse events included anemia (18 percent in both groups), pneumonia (10 percent vs 7 percent), thrombocytopenia (7 percent in both groups), neutropenia (6 percent vs 7 percent), and decreased platelet count (4 percent vs 5 percent).

“Once weekly carfilzomib at 70 mg/m2 significantly prolonged progression-free survival versus the twice-weekly schedule. Overall safety was comparable between the groups. Once weekly carfilzomib appears safe and more effective with a convenient dosing regimen versus the twice-weekly schedule for the treatment of patients with relapsed and refractory multiple myeloma,” concluded the authors.

For further reference log on to https://doi.org/10.1016/S1470-2045(18)30354-1


Source: With inputs from The Lancet Oncology

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted